Where is Serova located?

Serova is headquartered in London, United Kingdom.

Where does Serova rank among its competitors?

Serova ranks 3048th amongst 2479 active competitors, of which 835 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Serova?

Serova's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Serova - 2026 Company Profile, Funding & Competitors

Serova is a funded company based in London (United Kingdom), founded in 2025. It operates as a Personalized cancer vaccine platform using tumour biology to design individualized immunotherapies. The company has 2479 active competitors, including 835 funded and 615 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Personalized cancer vaccine platform using tumour biology to design individualized immunotherapies. It uses longitudinal and multi-site tumour data to identify vaccine targets and select tumour-driving mutations. Its computational workflows analyze tumour dynamics and evolving disease biology to support the design of patient-specific cancer vaccines tailored to the disease state at treatment. The platform is intended to help oncology researchers and healthcare providers develop individualized immunotherapies addressing tumour heterogeneity and disease progression.

Key Metrics

Founded Year

2025

Location

London, United Kingdom

Stage

Funding Raised

Investors

Belief Capital

Ranked

3048^th among 3048 competitors

Similar Companies

VBI Vaccines & 37 more

View Serova's full profile

Serova is a funded company. Serova has 1 institutional investor.

View details of Serova's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Serova include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Serova, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
10th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
3048th	Serova 2025, London (United Kingdom), Funding Raised	Personalized cancer vaccine platform using tumour biology to design individualized immunotherapies	-	Belief Capital	-